Between 25% and 33% of patients after radical prostatectomy experience a relapse of the disease. The risk of relapse increases in patients with risk factors up to 50%-80%. For a long time, adjuvant radiotherapy has been considered the standard of care. Four large prospective trials, that compared adjuvant and salvage radiotherapy in patients with biochemical relapse, showed the superiority of the adjuvant approach in biochemical and local relapse-free survival, but no consistent benefit in long-term endpoints (i.e., metastasis-free survival, overall survival, or carcinoma-specific survival) at the expense of increased urinary and bowel toxicity. Three large international studies comparing adjuvant and salvage radiotherapy paved the way toward early salvage radiotherapy. However, the optimal threshold of the PSA level (range of 0.2-0.5 ng/mL) for initiating early salvage radiotherapy remains unresolved and still poses a challenge in everyday clinical practice when balancing the need for early radiotherapy and the associated toxicity. Imprecise stratification of biochemical relaps patients according to the risk of clinical relapse drives efforts to find additional molecular biomarkers that would improve the timing of the salvage therapy.

Department of Oncology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czechia

Department of Radiology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czechia

Department of Urology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czechia

Zobrazit více v PubMed

Barbieri C, Shoag J. Clinical Variability and Molecular Heterogeneity in Prostate Cancer. Asian J Androl (2016) 18:543–8. 10.4103/1008-682x.178852 PubMed DOI PMC

Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol (2020) 31:1119–34. 10.1016/j.annonc.2020.06.011 PubMed DOI

Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant Radiotherapy Versus Early Salvage Radiotherapy Following Radical Prostatectomy (TROG 08.03/ANZUP RAVES): A Randomised, Controlled, Phase 3, Non-Inferiority Trial. Lancet Oncol (2020) 21:1331–40. 10.1016/s1470-2045(20)30456-3 PubMed DOI

Tao R, Dai J, Bai Y, Yang J, Sun G, Zhang X, et al. The Prognosis Benefits of Adjuvant versus Salvage Radiotherapy for Patients After Radical Prostatectomy With Adverse Pathological Features: A Systematic Review and Meta-Analysis. Radiat Oncol (2019) 14:197. 10.1186/s13014-019-1384-z PubMed DOI PMC

Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjuvant Radiotherapy Versus Wait-And-See After Radical Prostatectomy: 10-Year Follow-Up of the ARO 96-02/AUO AP 09/95 Trial. Eur Urol (2014) 66:243–50. 10.1016/j.eururo.2014.03.011 PubMed DOI

Mottet N, van den Bergh RCN, Briers E. EAU-EANM- ESTRO-ESUR-SIOG Guidelines on Prostate Cancer 2020. In: European Association of Urology Guidelines. Arnhem, The Netherlands: European Association of Urology Guidelines Office; (2020).

Bhindi B, Lokeshwar SD, Klaassen Z, Klotz L, Wallis CJ. Systematic Review and Meta-Analysis of Trials Evaluating the Role of Adjuvant Radiation After Radical Prostatectomy for Prostate Cancer: Implications for Early Salvage. Can Urol Assoc J (2020) 14:330–6. 10.5489/cuaj.6440 PubMed DOI PMC

Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial. J Urol (2009) 181:956–62. 10.1016/j.juro.2008.11.032 PubMed DOI PMC

Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative Radiotherapy After Radical Prostatectomy for High-Risk Prostate Cancer: Long-Term Results of a Randomised Controlled Trial (EORTC Trial 22911). The Lancet (2012) 380:2018–27. 10.1016/s0140-6736(12)61253-7 PubMed DOI

Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, et al. FinnProstate Group: Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients With Positive Margins or Extracapsular Extension. Eur Urol (2019) 76:586–95. 10.1016/j.eururo.2019.07.001 PubMed DOI

Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. J Urol (2018) 199:990–7. 10.1016/j.juro.2018.01.002 PubMed DOI

Plousard G, Staerman F, Pierrevelcin J. . Committee of Cancerology of the Association of French Urology. Predictive Factors of Oncologic Outcomes in Patients Who Do Not Achieve Undetectable Prostate Specific Antigen After Radical Prostatectomy. J Urol (2013) 190:1750–6. 10.1016/j.juro.2013.04.073 PubMed DOI

Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of Radiotherapy After Radical Prostatectomy (RADICALS-RT): A Randomised, Controlled Phase 3 Trial. The Lancet (2020) 396:1413–21. 10.1016/s0140-6736(20)31553-1 PubMed DOI

Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, et al. Adjuvant Radiotherapy Versus Early Salvage Radiotherapy Plus Short-Term Androgen Deprivation Therapy in Men With Localised Prostate Cancer After Radical Prostatectomy (GETUG-AFU 17): A Randomised, Phase 3 Trial. Lancet Oncol (2020) 21:1341–52. 10.1016/s1470-2045(20)30454-x PubMed DOI

Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, et al. Adjuvant or Early Salvage Radiotherapy for the Treatment of Localised and Locally Advanced Prostate Cancer: A Prospectively Planned Systematic Review and Meta-Analysis of Aggregate Data. The Lancet (2020) 396:1422–31. 10.1016/s0140-6736(20)31952-8 PubMed DOI PMC

Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. NRG Oncology RTOG: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med (2017) 376:417–28. 10.1056/nejmoa1607529 PubMed DOI PMC

Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, et al. Salvage Radiotherapy With or Without Short-Term Hormone Therapy for Rising Prostate-Specific Antigen Concentration After Radical Prostatectomy (GETUG-AFU 16): A Randomised, Multicentre, Open-Label Phase 3 Trial. Lancet Oncol (2016) 17:747–56. 10.1016/s1470-2045(16)00111-x PubMed DOI

Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, et al. Short-Term Androgen Deprivation Therapy Combined With Radiotherapy as Salvage Treatment After Radical Prostatectomy for Prostate Cancer (GETUG-AFU 16): A 112-Month Follow-Up of a Phase 3, Randomised Trial. Lancet Oncol (2019) 20:1740–9. 10.1016/s1470-2045(19)30486-3 PubMed DOI

Fossati N, Robesti D, Karnes RJ, Soligo M, Boorjian SA, Bossi A, et al. Assessing the Role and Optimal Duration of Hormonal Treatment in Association With Salvage Radiation Therapy After Radical Prostatectomy: Results From a Multi-Institutional Study. Eur Urol (2019) 76:443–9. 10.1016/j.eururo.2019.02.004 PubMed DOI

Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, et al. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-Term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol (2020) 6:735–43. 10.1001/jamaoncol.2020.0109 PubMed DOI PMC

Abugharib A, Jackson WC, Tumati V, Dess RT, Lee JY, Zhao SG, et al. Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. J Urol (2017) 197:662–8. 10.1016/j.juro.2016.08.106 PubMed DOI

Moreira DM, Presti JC, Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, et al. Natural History of Persistently Elevated Prostate Specific Antigen After Radical Prostatectomy: Results From the SEARCH Database. J Urol (2009) 182:2250–6. 10.1016/j.juro.2009.07.022 PubMed DOI

Xiang C, Liu X, Chen S, Wang P. Prediction of Biochemical Recurrence Following Radiotherapy Among Patients With Persistent PSA After Radical Prostatectomy: A Single-Center Experience. Urol Int (2018) 101:47–55. 10.1159/000488536 PubMed DOI

Rogers CG, Khan MA, Craig Miller M, Veltri RW, Partin AW. Natural History of Disease Progression in Patients Who Fail to Achieve an Undetectable Prostate-Specific Antigen Level After Undergoing Radical Prostatectomy. Cancer (2004) 101:2549–56. 10.1002/cncr.20637 PubMed DOI

Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic Value of Biochemical Recurrence Following Treatment With Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol (2019) 75:967–87. 10.1016/j.eururo.2018.10.011 PubMed DOI

Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural History of Progression After PSA Elevation Following Radical Prostatectomy. J Urol (1999) 281:1591–7. 10.1001/jama.281.17.1591 PubMed DOI

Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, et al. Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time From Surgery to Recurrence. Eur Urol (2011) 59:893–9. 10.1016/j.eururo.2011.02.026 PubMed DOI

Kristiansen G. Markers of Clinical Utility in the Differential Diagnosis and Prognosis of Prostate Cancer. Mod Pathol (2018) 31(S1):S143–S155. 10.1038/modpathol.2017.168 PubMed DOI

Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, et al. Early Salvage Radiotherapy Following Radical Prostatectomy. Eur Urol (2014) 65:1034–43. 10.1016/j.eururo.2013.08.013 PubMed DOI

Ohri N, Dicker AP, Trabulsi EJ, Showalter TN. Can Early Implementation of Salvageradiotherapy for Prostate Cancer Improve the Therapeutic Ratio? A Systematic Review and Regression Meta-Analysis With Radiobiological Modelling. Eur J Cancer (2012) 48:837–44. 10.1016/j.ejca.2011.08.013 PubMed DOI PMC